 This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis RA who are naive to Methotrexate MTX therapy. Rheumatoid Factor RF-positive and RF-negative patients will be enrolled and will be allocated equally between 3 treatment arms. 